Michel Detheux compensation by year
iTeos Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2023 | FY2024 |
|---|---|---|
| Salary | $578,863 | $628,684 |
| Bonus | $0 | $0 |
| Stock awards | $295,200 | $0 |
| Option awards | $4,428,800 | $4,965,264 |
| Non-equity incentive | $384,516 | $421,014 |
| Pension and deferred compensation | $0 | $0 |
| All other | $80,395 | $70,695 |
| Total | $5,767,774 | $6,085,657 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: iTeos Therapeutics, Inc. DEF 14A filed April 24, 2025, accession 0000950170-25-057666, and prior-year filings.
How this page was built: the iTeos Therapeutics, Inc. filed document, accession 0000950170-25-057666. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 30,000 | $230,400 | — |
| RSU | 3,125 | $24,000 | — |
| Option | 194,626 | — | $16.66 |
| Option | 110,156 | — | $36.21 |
| Option | 9,000 | — | $41.58 |
| Option | 590,400 | — | $11.58 |
Per the Outstanding Equity Awards at Fiscal Year-End table in iTeos Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
43 Form 4 lines since the FY2024 proxy (filed April 24, 2025)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-08-29 | Disposition to the issuer derivative | — | 52,700 | — | 0 |
| 2025-08-29 | Disposition to the issuer derivative | — | 94,336 | — | 0 |
| 2025-08-29 | U | — | 94,027 | — | 0 |
| 2025-08-29 | Disposition to the issuer derivative | — | 185,000 | — | 0 |
| 2025-08-29 | Disposition to the issuer derivative | — | 14,185 | — | 0 |
| 2025-08-29 | Disposition to the issuer derivative | — | 17,544 | — | 0 |
| 2025-08-29 | Disposition to the issuer derivative | — | 444,815 | — | 0 |
| 2025-08-29 | Disposition to the issuer derivative | — | 50,128 | — | 0 |
The 8 most recent of 43 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
iTeos Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Michel Detheux · this page | Chief Executive Officer | $6,085,657 |
| David Feltquate | Chief Medical Officer | $5,055,005 |
| Matthew Call | Chief Operating Officer | $2,617,730 |
Board service
iTeos Therapeutics board · FY2023–FY2024How this board is paid
Company policy: iTeos Therapeutics pays directors a $40,000 cash retainer and $280,962 in Options. As stated in iTeos Therapeutics's FY2024 proxy.
Committees
Science and Technology
The full iTeos Therapeutics compensation record
free company briefThis page is one person within iTeos Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order iTeos Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are iTeos Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.